Neuroendocrine abnormalities in Parkinson's disease

Research output: Contribution to journalReview article


Neuroendocrine abnormalities are common in Parkinson's disease (PD) and include disruption of melatonin secretion, disturbances of glucose, insulin resistance and bone metabolism, and body weight changes. They have been associated with multiple non-motor symptoms in PD and have important clinical consequences, including therapeutics. Some of the underlying mechanisms have been implicated in the pathogenesis of PD and represent promising targets for the development of disease biomarkers and neuroprotective therapies. In this systems-based review, we describe clinically relevant neuroendocrine abnormalities in Parkinson's disease to highlight their role in overall phenotype. We discuss pathophysiological mechanisms, clinical implications, and pharmacological and non-pharmacological interventions based on the current evidence. We also review recent advances in the field, focusing on the potential targets for development of neuroprotective drugs in Parkinson's disease and suggest future areas for research.


  • Eduardo De Pablo-Fernández
  • David P Breen
  • Pierre M Bouloux
  • Roger A Barker
  • Thomas Foltynie
  • Thomas T Warner
External organisations
  • University of Cambridge
Original languageEnglish
Pages (from-to)176-185
JournalJournal of Neurology, Neurosurgery and Psychiatry
Early online date2016 Oct 31
Publication statusPublished - 2017
Publication categoryResearch